Cargando…

Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon

Some therapies for diabetes increase the risk of hypoglycaemia, in particular all insulins and insulin secretagogues, including the glinides and sulfonylureas. Hypoglycaemia remains a major limiting factor to successful glycaemic management, despite the availability of prevention options such as ins...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thieu, Vivian T., Mitchell, Beth D., Varnado, Oralee J., Frier, Brian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079012/ https://www.ncbi.nlm.nih.gov/pubmed/31820562 http://dx.doi.org/10.1111/dom.13941

Ejemplares similares

New uses and formulations of glucagon for hypoglycaemia
por: Beato-Víbora, Pilar I, et al.
Publicado: (2019)

Factors associated with fear of hypoglycaemia among the T1D Exchange Glu population in a cross-sectional online survey
por: Liu, Jingwen, et al.
Publicado: (2020)

Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
por: Heller, S. R., et al.
Publicado: (2015)

Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study
por: Suico, Jeffrey G., et al.
Publicado: (2020)

Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes
por: Ali, Namam, et al.
Publicado: (2020)

Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia
por: Kristensen, Peter L, et al.
Publicado: (2016)

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
por: Signorovitch, J E, et al.
Publicado: (2013)

Hypoglycaemia in adults with insulin‐treated diabetes in the UK: self‐reported frequency and effects
por: Frier, B. M., et al.
Publicado: (2015)

Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results
por: Pantalone, Kevin M., et al.
Publicado: (2020)

Cognitive deficits associated with impaired awareness of hypoglycaemia in type 1 diabetes
por: Hansen, Tor I., et al.
Publicado: (2017)

Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
por: Frier, Brian M., et al.
Publicado: (2019)

Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies
por: Demirbilek, Huseyin, et al.
Publicado: (2023)

Evaluation of Hypoglycaemia with Non-Invasive Sensors in People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia
por: Elvebakk, Ole, et al.
Publicado: (2018)

Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia
por: Reviriego, J, et al.
Publicado: (2008)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016)

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting
por: Seaquist, Elizabeth R., et al.
Publicado: (2018)

Author Correction: Evaluation of Hypoglycaemia with Non-Invasive Sensors in People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia
por: Elvebakk, Ole, et al.
Publicado: (2019)

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
por: Varnado, Oralee J, et al.
Publicado: (2022)

Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene–related peptide inhibitors vs other preventive migraine treatments in the United States
por: Varnado, Oralee J, et al.
Publicado: (2022)

Importance of de-escalating anti-diabetic medication to prevent hypoglycaemia
por: Abid, Syed, et al.
Publicado: (2020)

Development and validation of the hypoglycaemia problem-solving scale for people with diabetes mellitus
por: Wu, Fei-Ling, et al.
Publicado: (2016)

Hypoglycaemia in older home-dwelling people with diabetes- a scoping review
por: Hermann, Monica, et al.
Publicado: (2021)

Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain
por: Osumili, Beatrice, et al.
Publicado: (2022)

Hypoglycaemia in Type 2 diabetes
por: Amiel, S A, et al.
Publicado: (2008)

Hypoglycaemia and cardiac arrhythmias in diabetes
por: Andersen, Andreas, et al.
Publicado: (2020)

Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin‐treated type 2 diabetes: Results from a real‐world nested case‐control study
por: Settles, Julie, et al.
Publicado: (2022)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020)

Reducing the burden of hypoglycaemia in people with diabetes through increased understanding: design of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypo‐RESOLVE) project
por: de Galan, B. E., et al.
Publicado: (2020)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Cognitive, behavioural and psychological barriers to the prevention of severe hypoglycaemia: A qualitative study of adults with type 1 diabetes
por: Speight, Jane, et al.
Publicado: (2014)

Hypoglycæmia
Publicado: (1934)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Increase in hypoglycaemia and hyperglycaemia in people with diabetes admitted to hospital during COVID-19 pandemic
por: Ruan, Yue, et al.
Publicado: (2023)

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years
por: Boustani, M. A., et al.
Publicado: (2016)

Type 2 diabetes patients’ views on prevention of hypoglycaemia – a mixed methods study investigating self-management issues and self-identified causes of hypoglycaemia
por: Crutzen, Stijn, et al.
Publicado: (2021)

The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes
por: Levy, Brian L, et al.
Publicado: (2016)

A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study
por: Heller, Simon R., et al.
Publicado: (2021)

The impact of hypoglycaemia awareness status on regional brain responses to acute hypoglycaemia in men with type 1 diabetes
por: Dunn, Joel T., et al.
Publicado: (2018)

Impaired awareness of hypoglycaemia in women with type 1 diabetes in pregnancy: Hypoglycaemia fear, glycaemic and pregnancy outcomes
por: Bahrami, Jasmine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1p1v5avijgj279m27m9nel2ffv